Journal of Pharmacy and Pharmacology · 1979 · 18 citations · 20 references
MedicineNeurosciencePharmacologyDrug MetabolismNeurochemistryNeuropharmacologyMonoamine NeurochemistryNeurochemical PharmacologySerotonergic PharmacologyBrain Drug MetabolismMonoamine MetabolismMonoamine Oxidase InhibitionMonoamine Oxidase InhibitorsMonoamine Oxidase InvolvementMonoamine PharmacologyMonoamine TurnoverOral Treatment
Rats were administered toloxatone 100 mg kg-1 p.o., and killed 0.5 to 8 hours later. Toloxatone reversibly inhibited type A MAO, but did not affect the activity of type B MAO in whole brain. Cerebral concentrations of noradrenaline, dopamine and 5-hydroxytryptamine were increased after toloxatone, while their metabolite concentrations were reduced. Synaptosomal uptake processes of these amines were not altered by tolaxatone.
20